INHIBIDORES DE LA PROTEINA QUINASA C

Un compuesto de la Fórmula: **(Ver fórmula)** en la que: R1 es **(Ver fórmula)** o un resto alquilglucosa; R1'' es hidrógeno, alquilo C1-C4, ciclopropilmetilo, aminoalquilo, monoalquilaminoalquilo o dialquilaminoalquilo; R2 y R2'' son independientemente hidrógeno, alquilo, alcoxialquilo, hidroxialquilo, alquil C1-C3-tio, S(O)alquilo C1-C3 o CF3; R3 es hidrógeno o CH3CO-; R4, R4'', R5, R5'', R6, R6'', R7 y R7'' son independientemente hidrógeno, halógeno, alquilo, hidroxi, alcoxi, -COO(alquilo C1-C3), CF3, nitro, amino, acetilamino, monoalquilamino, dialquilamino, alquiltio o S(O)alquilo C1-C3; n es 1, 2, 3, 4, 5 ó 6; o una sal o solvato farmacéuticamente aceptable del mismo. The present invention discloses compounds of the general formula: The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.